<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Measuring AI Progress in Drug Discovery: A Reproducible Leaderboard for the Tox21 Challenge - Health AI Hub</title>
    <meta name="description" content="This paper addresses the lack of clear progress in AI-driven toxicity prediction for drug discovery, a field significantly impacted by deep learning. It introdu">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Measuring AI Progress in Drug Discovery: A Reproducible Leaderboard for the Tox21 Challenge</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.14744v1" target="_blank">2511.14744v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-18
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Antonia Ebner, Christoph Bartmann, Sonja Topf, Sohvi Luukkonen, Johannes Schimunek, G√ºnter Klambauer
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.14744v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.14744v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper addresses the lack of clear progress in AI-driven toxicity prediction for drug discovery, a field significantly impacted by deep learning. It introduces a reproducible leaderboard hosted on Hugging Face, utilizing the original Tox21 Challenge dataset, which was previously altered in subsequent benchmarks. The study reveals that early deep learning methods from 2015 and 2017 remain highly competitive, questioning the extent of substantial advancement in toxicity prediction over the past decade.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is crucial for drug discovery and development as it provides a realistic assessment of AI's current capabilities in predicting drug toxicity. Accurate toxicity prediction is vital for reducing attrition rates in drug development, ensuring drug safety, and accelerating the identification of safer therapeutic compounds for patients.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is the prediction of drug toxicity and bioactivity using deep learning methods to accelerate and improve the safety and efficacy assessment of potential drug candidates in the pharmaceutical research pipeline. This helps identify harmful compounds early, reducing risks in drug development and ultimately for patients.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Deep learning's rise transformed drug discovery, with the 2015 Tox21 Data Challenge marking a pivotal moment where deep neural networks surpassed traditional toxicity prediction methods.</li>
                    
                    <li>Subsequent integrations of the Tox21 dataset into benchmarks like MoleculeNet and Open Graph Benchmark led to data alterations (imputed or manufactured labels), compromising cross-study comparability and obscuring true progress.</li>
                    
                    <li>To re-establish comparability and measure progress, the authors developed and hosted a reproducible leaderboard on Hugging Face, utilizing the *original* Tox21 Challenge dataset.</li>
                    
                    <li>The leaderboard evaluates a set of baseline and representative AI methods for toxicity prediction.</li>
                    
                    <li>A key finding is that the original 2015 Tox21 winner, the ensemble-based DeepTox method, and 2017 descriptor-based self-normalizing neural networks (SNNs) continue to perform competitively, ranking among the top methods.</li>
                    
                    <li>This persistent competitiveness of older methods suggests that substantial, breakthrough progress in AI-driven toxicity prediction may not have been achieved over the past decade.</li>
                    
                    <li>All evaluated baselines and models are made publicly accessible for inference via standardized API calls to Hugging Face Spaces, promoting transparency and future research.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved creating and hosting a reproducible leaderboard on Hugging Face, explicitly using the unaltered, original Tox21 Challenge dataset. A selection of baseline and representative deep learning models for toxicity prediction were evaluated on this standardized platform, and their performance was made publicly accessible via standardized API calls.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary finding is that the original Tox21 winner (ensemble-based DeepTox) from 2015 and descriptor-based self-normalizing neural networks from 2017 remain highly competitive and rank among the top methods for toxicity prediction on the original dataset. This suggests that despite a decade of intense research, substantial overarching progress in AI-driven toxicity prediction has not been clearly demonstrated.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>By providing a clearer picture of AI's current capabilities in toxicity prediction, this work can help pharmaceutical companies and researchers make more informed decisions about which AI models to integrate into drug discovery pipelines. This could lead to more efficient and reliable preclinical screening, potentially reducing the development of toxic compounds, improving drug safety profiles, and ultimately bringing safer and more effective medications to patients faster.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The observed plateau in performance, where older models remain top-tier, suggests a limitation in current AI methodologies for toxicity prediction, highlighting a potential bottleneck in achieving substantially improved predictive power. Previous alterations to the Tox21 dataset in other benchmarks had also limited the comparability and validity of prior comparative studies.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The paper implicitly suggests a need for novel AI paradigms, architectural innovations, or perhaps new data representations that can demonstrably surpass existing methods in toxicity prediction. Future research should aim to understand why current methods have plateaued and explore strategies to achieve breakthrough improvements beyond the current state-of-the-art.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Toxicology</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Pharmaceutical Sciences</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Toxicity Prediction</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Tox21</span>
                    
                    <span class="tag tag-keyword">AI Benchmarking</span>
                    
                    <span class="tag tag-keyword">Reproducibility</span>
                    
                    <span class="tag tag-keyword">Pharmacology</span>
                    
                    <span class="tag tag-keyword">Computational Chemistry</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Deep learning's rise since the early 2010s has transformed fields like computer vision and natural language processing and strongly influenced biomedical research. For drug discovery specifically, a key inflection - akin to vision's "ImageNet moment" - arrived in 2015, when deep neural networks surpassed traditional approaches on the Tox21 Data Challenge. This milestone accelerated the adoption of deep learning across the pharmaceutical industry, and today most major companies have integrated these methods into their research pipelines. After the Tox21 Challenge concluded, its dataset was included in several established benchmarks, such as MoleculeNet and the Open Graph Benchmark. However, during these integrations, the dataset was altered and labels were imputed or manufactured, resulting in a loss of comparability across studies. Consequently, the extent to which bioactivity and toxicity prediction methods have improved over the past decade remains unclear. To this end, we introduce a reproducible leaderboard, hosted on Hugging Face with the original Tox21 Challenge dataset, together with a set of baseline and representative methods. The current version of the leaderboard indicates that the original Tox21 winner - the ensemble-based DeepTox method - and the descriptor-based self-normalizing neural networks introduced in 2017, continue to perform competitively and rank among the top methods for toxicity prediction, leaving it unclear whether substantial progress in toxicity prediction has been achieved over the past decade. As part of this work, we make all baselines and evaluated models publicly accessible for inference via standardized API calls to Hugging Face Spaces.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>